AbCellera Biologics (ABCL) Equity Average (2020 - 2025)
AbCellera Biologics' Equity Average history spans 6 years, with the latest figure at $985.6 million for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 9.96% year-over-year to $985.6 million, compared with a TTM value of $985.6 million through Sep 2025, down 9.96%, and an annual FY2024 reading of $1.1 billion, down 7.43% over the prior year.
- Equity Average for Q3 2025 was $985.6 million at AbCellera Biologics, down from $1.0 billion in the prior quarter.
- The five-year high for Equity Average was $1.2 billion in Q4 2022, with the low at $893.8 million in Q1 2021.
- Average Equity Average over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2022.
- Year-over-year, Equity Average skyrocketed 1002.53% in 2021 and then dropped 9.96% in 2025.
- Tracing ABCL's Equity Average over 5 years: stood at $989.6 million in 2021, then grew by 25.48% to $1.2 billion in 2022, then decreased by 5.97% to $1.2 billion in 2023, then dropped by 8.6% to $1.1 billion in 2024, then dropped by 7.64% to $985.6 million in 2025.
- Per Business Quant, the three most recent readings for ABCL's Equity Average are $985.6 million (Q3 2025), $1.0 billion (Q2 2025), and $1.0 billion (Q1 2025).